AMSTERDAM, September 22 /PRNewswire/ -- Kiadis Pharma announced today that its lead product ATIR(TM) has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation.
"Following the orphan drug designation granted by the FDA for our lead product ATIR(TM), this is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.
The EMEA's orphan drug designation is reserved for new therapies being developed to treat life-threatening or chronically debilitating diseases or conditions that are relatively rare in the European Union and for which no satisfactory therapy is available. The orphan drug designation provides for incentives to support research and development, exemption from user fees and a ten-year period of market exclusivity in the European Union after product approval.
For the complete press release please go to: http://www.kiadis.com/news
About Kiadis Pharma
Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.
|SOURCE Kiadis Pharma|
Copyright©2008 PR Newswire.
All rights reserved